Literature DB >> 8559527

Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein.

P A Benn1, D Horne, S Briganti, J F Rodis, J M Clive.   

Abstract

OBJECTIVE: To evaluate the clinical significance of a second-trimester elevated maternal serum hCG in women carrying singleton, chromosomally normal fetuses.
METHODS: The results of second-trimester maternal serum screening (alpha-fetoprotein [MSAFP], hCG, and unconjugated estriol) for 25,438 women were reviewed, and those with hCG values exceeding 3.0 multiples of the median (MoM) were identified. A control population was selected only on the basis of samples accessioned by the laboratory at the same time as the study group. Follow-up information was collected from physicians' offices for both groups. Incidence of fetal or neonatal loss (spontaneous abortion, fetal death, and neonatal death combined), preterm birth (before 37 weeks' gestation), small for gestational age, and preeclampsia were compared.
RESULTS: Three hundred twenty-two women (1.3%) had hCG levels exceeding 3.0 MoM. In addition to chromosomal abnormalities and fetal death at the time of testing, this group showed a significantly higher incidence of fetal or neonatal death, preterm birth, low birth weight, and preeclampsia than did controls. For patients with elevated second-trimester hCG, many of the preterm deliveries occurred before 34 weeks' gestation. Logistic regression analysis indicated that hCG, MSAFP, and race were significant independent factors in predicting risk for adverse outcome.
CONCLUSIONS: Similar to elevated AFP, elevated hCG is associated with poor pregnancy outcome. By combining the results of the two tests, it may be possible to improve substantially the identification of patients at very high risk for adverse outcomes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8559527     DOI: 10.1016/0029-7844(95)00390-8

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

1.  A test of maternal human chorionic gonadotropin during pregnancy as an adaptive filter of human gestations.

Authors:  Tim A Bruckner; Katherine B Saxton; Michelle Pearl; Robert Currier; Martin Kharrazi
Journal:  Proc Biol Sci       Date:  2012-09-26       Impact factor: 5.349

2.  Low-dose aspirin for pre-eclampsia prevention in twins with elevated human chorionic gonadotropin.

Authors:  A G Euser; T D Metz; A A Allshouse; K D Heyborne
Journal:  J Perinatol       Date:  2016-04-07       Impact factor: 2.521

3.  The role of unexplained high serum alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in the second trimester to determine poor obstetric outcomes.

Authors:  Hümeyra Öztürk; Salim Erkaya; Sibel Altınbaş; Burak Karadağ; Nazan Vanlı Tonyalı; Demet Özkan
Journal:  Turk J Obstet Gynecol       Date:  2014-09-15

4.  Update and Review: Maternal Serum Screening.

Authors:  K E Ormond
Journal:  J Genet Couns       Date:  1997-12       Impact factor: 2.537

5.  Autism Spectrum Disorder Risk in Relation to Maternal Mid-Pregnancy Serum Hormone and Protein Markers from Prenatal Screening in California.

Authors:  Gayle C Windham; Kristen Lyall; Meredith Anderson; Martin Kharrazi
Journal:  J Autism Dev Disord       Date:  2016-02

6.  FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.

Authors:  Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-03       Impact factor: 3.561

Review 7.  Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis.

Authors:  Rachel K Morris; Jeltsje S Cnossen; Marloes Langejans; Stephen C Robson; Jos Kleijnen; Gerben Ter Riet; Ben W Mol; Joris A M van der Post; Khalid S Khan
Journal:  BMC Pregnancy Childbirth       Date:  2008-08-04       Impact factor: 3.007

8.  Better prediction for FGR (fetal growth restriction) with the sFlt-1/PIGF ratio: A case-control study.

Authors:  Valeria Visan; Ioana Sadiye Scripcariu; Demetra Socolov; Amelia Costescu; Daniela Rusu; Razvan Socolov; Andreea Avasiloaiei; Lucian Boiculese; Cristina Dimitriu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 9.  The Prenatal Hormone Milieu in Autism Spectrum Disorder.

Authors:  Whitney Worsham; Susan Dalton; Deborah A Bilder
Journal:  Front Psychiatry       Date:  2021-07-01       Impact factor: 4.157

10.  False-Positive Maternal Serum Screens in the Second Trimester as Markers of Placentally Mediated Complications Later in Pregnancy: A Systematic Review and Meta-Analysis.

Authors:  Christy L Pylypjuk; Joel Monarrez-Espino
Journal:  Dis Markers       Date:  2021-06-04       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.